文献速递炎症性肠病

肛周瘘管性克罗恩病的临床试验终点

Clinical Trial Endpoints for Perianal Fistulizing Crohn's Disease.
PubMed 文献 · Am J Gastroenterol · 2026-01-08

本文综述了肛周瘘管性克罗恩病(pCD)随机对照试验(RCT)终点设计的挑战,分析了10项III/IV期RCT的主要终点及事后分析,发现临床瘘管应答/缓解缺乏通用定义,多数试验基于未正式验证的体格检查评估临床应答,仅一项采用临床与影像学联合终点。五种评估瘘管闭合/愈合、临床缓解和患者报告结局的终点被认为反映临床有意义变化,但均不具可重复性或合理效应量。作者建议未来试验采用临床与影像学共同主要终点。

要点

  • pCD的RCT缺乏专门验证的主要终点,导致治疗推荐欠佳。
  • 多数试验基于未正式验证的体格检查评估临床应答,缺乏通用定义。
  • 五种终点反映临床有意义变化,但均不具可重复性或合理效应量。

核心结论

  • pCD临床试验缺乏高质量RCT和专门验证的主要终点,导致治疗推荐欠佳。
  • 现有终点均不具可重复性或合理效应量,未来试验应采用临床与影像学共同主要终点。

研究设计与样本

  • 综述分析了10项pCD III/IV期RCT的主要终点及事后分析,结合监管指南提供专家意见。

主要发现

  • 10项pCD III/IV期RCT的主要终点分析显示临床瘘管应答/缓解缺乏通用定义。
  • 多数试验基于未正式验证的体格检查评估临床应答,仅一项采用临床与影像学联合终点。
  • 五种评估瘘管闭合/愈合、临床缓解和患者报告结局的终点被认为反映临床有意义变化。
  • 上述五种终点均不具可重复性或合理效应量,安慰剂背景噪声或应答率不低。

关键数值与推荐

  • 五种终点评估瘘管闭合/愈合、临床缓解和患者报告结局,被认为反映临床有意义变化。
  • 未来试验应采用临床与影像学共同主要终点,以同时捕捉患者感受和客观疾病活动度。

临床怎么用

  • 未来pCD临床试验应采用临床与影像学共同主要终点评估新疗法。
  • 需建立清晰定义、客观且标准化的pCD临床试验终点以改善患者结局。

局限性

  • pCD的RCT设计受安慰剂应答率和治疗效应量随时间变化影响,且受入组前手术和药物干预影响。
  • 现有终点缺乏正式验证和通用定义,均不具可重复性或合理效应量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Perianal fistulizing Crohn's disease (pCD), a structurally damaging condition of the anorectum and perineum, can result in debilitating symptoms and significantly impair quality of life. The lack of high-quality randomized controlled trials (RCTs) with primary endpoints specifically validated for pCD has contributed to suboptimal treatment recommendations. This review discusses considerations for pCD RCTs and provides expert opinion on current endpoints in the context of guidance from regulatory authorities. A challenge designing pCD RCTs is that placebo response rates and treatment effect sizes can change over time and are influenced by surgical and medical interventions that are often required pre-enrollment. Analysis of the main endpoint in 10 pCD phase III/IV RCTs and post hoc analyses highlighted the lack of universal definitions for clinical fistula response/remission. Most trials assessed clinical response based on a physical examination, which has not been formally validated, and one used a combined clinical and radiological response endpoint. Five endpoints evaluating fistula closure/healing, clinical remission, and patient-reported outcomes were deemed to reflect clinically meaningful changes for patients. However, none were considered to be reproducible or show a reasonable effect size with low placebo background noise or response rates. Based on our evaluation, future trials should use coprimary clinical and radiologic assessments to capture both how the patient feels and an objective measure of disease activity. These findings reinforce the need for clearly defined, objective, and standardized endpoints for pCD clinical trials that will enable evaluation of novel therapies to improve patient outcomes.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Reinisch W, Atreya R, Rieder F, et al. Clinical Trial Endpoints for Perianal Fistulizing Crohn's Disease. Am J Gastroenterol. 2026. PMID: 41504318. doi:10.14309/ajg.0000000000003906

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。